| 王笑民,辛海,杨中,赵文硕,杨国旺,刘炬,唐武军,张青,韩冬,郁仁存.固本消瘤胶囊治疗晚期非小细胞肺癌的临床研究[J].,2004,(11):986-988 |
| 固本消瘤胶囊治疗晚期非小细胞肺癌的临床研究 |
| Clinical Study on Treatment of Advanced Stage Non Small Cell Lung Cancer |
| |
| DOI： |
| 中文关键词: 固本消瘤胶囊 非小细胞肺癌 生活质量 不良反应 减毒增效 |
| 英文关键词:Guben Xiaoliu capsule non small cell lung cancer quality of life adverse reaction reduce toxicity and enhance efficacy |
| 基金项目:北京市科委课题资助(No.952871600) |
|
| Hits: 1439 |
| Download times: 1897 |
| 中文摘要: |
| 目的观察固本消瘤胶囊(简称消瘤胶囊)治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法198例晚期NSCLC住院患者分为结合组(化疗加消瘤胶囊治疗)54例、中药组(单纯口服消瘤胶囊治疗)96例和化疗组(单用化疗治疗)48例,其中化疗组与结合组为随机对照观察,并对3组进行临床疗效、生存质量、不良反应和生存期等的观察。结果结合组、中药组、化疗组近期有效率(CR+PR)分别为167%、31%、83%,结合组疗效优于中药组和化疗组(P<005),且结合组、中药组患者在临床症状变化、生活质量方面均优于化疗组(P<005);中位生存期结合组、中药组、化疗组分别为12个月、15个月、9个月。治疗后1、2、3年生存率结合组分别为574%、111%和37%,中药组分别为677%、94%和31%,化疗组分别为396%、42%、0,生存率3组比较,结合组和中药组均优于化疗组(P<005)。结合组的化疗毒性发生率及毒性程度均较化疗组明显减轻(P<005)。结论固本消瘤胶囊治疗NSCLC具有一定缓解作用,并能提高患者的生活质量、延长生存期、减毒增效等作用。 |
| 英文摘要: |
| To observe the therapeutic effect of Guben Xiaoliu Capsule (GXC) in treating advanced stage non small cell lung cancer (NSCLC). MethodsOne hundred and ninety eight NSCLC in patients were divided into the integrative treated group 〔Group A, 54 patients treated with chemotherapy (CT) plus GXC〕, the TCM treated group (Group B, 96 patients treated with GXC alone) and the chemotherapeutic group (Group C, 48 patients treated with CT alone). Randomized controlled observation was applied to the Group A and C. The clinical effect, quality of life (QOL), adverse reaction and survival period in the three groups were observed. Results The immediate effective rate (CR+PR) in the Group A, B and C was 16 7%, 3 1% and 8 3%, respectively, in the Group A, it was better than that in the other two groups (P<0 05). The improvement of clinical symptoms and QOL in the Group A and B were superior to those in the Group C (P<0 05). The median survival rate in the three groups was 12, 15 and 9 months, respectively, the 1 , 2 and 3 year survival rate in Group A being 57 4%, 11 1% and 3 7%, respectively, in Group B, 67 7%, 9 4% and 3 1%, and in Group C, 39 6%, 4 2% and 0, respectively, comparison between the three groups showed that the survival rates in the former two were higher than those in Group C (P<0 05). Moreover, the incidence rate and degree of CT toxicity were milder in Group A than those in Group C (P<0 05). ConclusionGXC has definite effect in treating NSCLC, it could raise the QOL, prolong the survival period of patients, also reduce the toxicity and enhance the efficacy of CT. |
| View Full Text View/Add Comment Download reader |
|
|
|
